Shots:

• The P-III (NOTUS) trial evaluates the safety & efficacy of Dupixent (Q2W) vs PBO in patients (n=470 vs 465) aged 40-85yrs. (current/former smokers) with moderate-to-severe COPD & evidence of type 2 inflammation
• The trial met its 1EP by depicting a 34% reduction in COPD exacerbation over 52wks. & its 2EPs by showing an improved lung function from baseline was also by 139mL vs 57mL in FEV1 at 12wks. The results were consistent with those from the P-III (BOREAS) trial, the results for which were published in the ‘New England Journal of Medicine’
• The company expects to submit a sBLA for Dupixent, a fully human monoclonal antibody that inhibits the signaling of the IL-4 & IL-13 pathways

Ref: Globe Newswire | Image: Sanofi

Related News:- Sanofi,s Praluent (Alirocumab) Received EU’s CHMP Positive Opinion

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com